AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ospemifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives | 4749 | 128607-22-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an estrogen agonist/antagonist with tissue selective effects, its biological actions are mediated through binding to estrogen receptors, this binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| fu (Fraction unbound in plasma) | 0 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 26, 2013 | FDA | SHIONOGI INC | |
| Nov. 20, 2014 | EMA | Shionogi Limited |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hot flush | 310.13 | 36.75 | 87 | 1351 | 59401 | 90567608 |
| Labelled drug-drug interaction medication error | 193.10 | 36.75 | 45 | 1393 | 14537 | 90612472 |
| Vaginal discharge | 165.25 | 36.75 | 42 | 1396 | 19422 | 90607587 |
| Vaginal haemorrhage | 127.85 | 36.75 | 38 | 1400 | 31233 | 90595776 |
| No adverse event | 113.47 | 36.75 | 42 | 1396 | 67940 | 90559069 |
| Therapeutic response unexpected | 104.43 | 36.75 | 30 | 1408 | 21850 | 90605159 |
| Muscle spasms | 99.47 | 36.75 | 57 | 1381 | 251826 | 90375183 |
| Vulvovaginal burning sensation | 73.59 | 36.75 | 15 | 1423 | 2580 | 90624429 |
| Vulvovaginal discomfort | 67.18 | 36.75 | 14 | 1424 | 2683 | 90624326 |
| Inability to afford medication | 57.60 | 36.75 | 13 | 1425 | 3609 | 90623400 |
| Hyperhidrosis | 51.33 | 36.75 | 30 | 1408 | 136275 | 90490734 |
| Vulvovaginal pruritus | 51.04 | 36.75 | 12 | 1426 | 3981 | 90623028 |
| Off label use | 45.56 | 36.75 | 70 | 1368 | 1102182 | 89524827 |
| Labelled drug-disease interaction medication error | 38.96 | 36.75 | 6 | 1432 | 205 | 90626804 |
| Product prescribing error | 37.24 | 36.75 | 15 | 1423 | 30130 | 90596879 |
| Vulvovaginal pain | 36.94 | 36.75 | 9 | 1429 | 3465 | 90623544 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hot flush | 240.47 | 41.91 | 65 | 967 | 65971 | 110522296 |
| Vaginal discharge | 121.11 | 41.91 | 29 | 1003 | 17879 | 110570388 |
| Labelled drug-drug interaction medication error | 111.64 | 41.91 | 30 | 1002 | 29272 | 110558995 |
| Vaginal haemorrhage | 101.79 | 41.91 | 27 | 1005 | 25047 | 110563220 |
| Muscle spasms | 86.86 | 41.91 | 45 | 987 | 278112 | 110310155 |
| Therapeutic response unexpected | 79.52 | 41.91 | 22 | 1010 | 23821 | 110564446 |
| Vulvovaginal discomfort | 64.96 | 41.91 | 12 | 1020 | 2112 | 110586155 |
| No adverse event | 55.11 | 41.91 | 22 | 1010 | 73817 | 110514450 |
| Vulvovaginal burning sensation | 52.57 | 41.91 | 10 | 1022 | 2059 | 110586208 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03XC05 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Selective estrogen receptor modulators |
| FDA MoA | N0000000168 | Selective Estrogen Receptor Modulators |
| FDA EPC | N0000175826 | Estrogen Agonist/Antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50739 | estrogen receptor modulator |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
G03XC Selective estrogen receptor modulators 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Dyspareunia | indication | 71315007 | |
| Atrophic vulva | indication | 248861000 | DOID:14275 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 60MG | OSPHENA | DUCHESNAY | N203505 | Feb. 26, 2013 | RX | TABLET | ORAL | 8236861 | Aug. 11, 2026 | TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE |
| 60MG | OSPHENA | DUCHESNAY | N203505 | Feb. 26, 2013 | RX | TABLET | ORAL | 8236861 | Aug. 11, 2026 | TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE |
| 60MG | OSPHENA | DUCHESNAY | N203505 | Feb. 26, 2013 | RX | TABLET | ORAL | 8236861 | Aug. 11, 2026 | TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | MODULATOR | IC50 | 6.08 | WOMBAT-PK | CHEMBL | |||
| Estrogen receptor beta | Nuclear hormone receptor | ANTAGONIST | Ki | 6.39 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D08958 | KEGG_DRUG |
| 4032347 | VANDF |
| CHEBI:73275 | CHEBI |
| CHEMBL2105395 | ChEMBL_ID |
| C119141 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7349 | IUPHAR_LIGAND_ID |
| DB04938 | DRUGBANK_ID |
| B0P231ILBK | UNII |
| 1370971 | RXNORM |
| 199207 | MMSL |
| 29311 | MMSL |
| d08070 | MMSL |
| 014918 | NDDF |
| 716223004 | SNOMEDCT_US |
| C1313616 | UMLSCUI |
| 7859 | INN_ID |
| 3036505 | PUBCHEM_CID |
| B0P231ILBK | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Osphena | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55494-580 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 30 sections |